Takahiro Kobayashi

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Topics

Combination Therapy

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Myasthenia Gravis

Top Venues

International journal of clinical oncology

International journal of hematology

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. International journal of clinical oncology 29 (4) (2024)
Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. International journal of clinical oncology 29 (4) (2024)
Yasunori Kogure, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Tomohiro Shinozaki, Takahiro Yoshida, Ikuo Mori, Shinsuke Iida, Takahiro Maeda, Keisuke Kataoka
ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood (2024)
Yasunori Kogure, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Tomohiro Shinozaki, Takahiro Yoshida, Ikuo Mori, Shinsuke Iida, Takahiro Maeda, Keisuke Kataoka
ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood (2024)
Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. International journal of clinical oncology 29 (4) (2024)
Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. International journal of clinical oncology 29 (4) (2024)
Yasunori Kogure, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Tomohiro Shinozaki, Takahiro Yoshida, Ikuo Mori, Shinsuke Iida, Takahiro Maeda, Keisuke Kataoka
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood 143 (23) (2024)
Honami Sato, Takahiro Kobayashi, Yoshihiro Kameoka, Kazuaki Teshima, Atsushi Watanabe, Masahiro Yamada, Takaya Yamashita, Shinsuke Noguchi, Yoshihiro Michisita, Naohito Fujishima, Jun Kuroki, Naoto Takahashi
Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. International journal of clinical oncology (2024)
Jiro Kikuchi, Nobuyuki Kodama, Masataka Takeshita, Sho Ikeda, Takahiro Kobayashi, Yoshiaki Kuroda, Michihiro Uchiyama, Naoki Osada, Bjarne Bogen, Hiroshi Yasui, Naoto Takahashi, Akiyoshi Miwa, Yusuke Furukawa
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood advances (2022)
Honami Sato, Takahiro Kobayashi, Nanako Fujita, Takaya Yamashita, Akihiro Kitadate, Tomoko Yoshioka, Miho Nara, Yoshihiro Kameoka, Masatomo Miura, Naoto Takahashi
Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia. Cancer chemotherapy and pharmacology 90 (3) (2022)
Takahiro Kobayashi, Kumi Ubukawa, Masumi Fujishima, Naoto Takahashi
Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis. International journal of hematology 113 (4) (2021)
Takaya Yamashita, Kazuhiro Ikegame, Fumiko Ito, Takahiro Kobayashi, Miho Nara, Naohito Fujishima, Akira Anbai, Takayuki Inoue, Katsuji Kaida, Hidenori Tanaka, Naoto Takahashi
Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor. Bone marrow transplantation 54 (10) (2019)
Takahiro Kobayashi, Masatomo Miura, Maiko Abumiya, Yumiko Akamine, Fumiko Ito, Naoto Takahashi
Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. Medical oncology (Northwood, London, England) 36 (6) (2019)
Takahiro Kobayashi, Yong-Mei Guo, Takaya Yamashita, Miho Nara, Tomoko Yoshioka, Yoshihiro Kameoka, Takahiro Fukuda, Naoto Takahashi
Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation. International journal of hematology 109 (3) (2019)